Oxycodone. Pharmacological profile and clinical data in chronic pain management

Minerva Anestesiologica

Volumn 71, Issue 7-8, 2005, Pages 451-460

  Coluzzi, Flaminia ^a,b   Mattia, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Acetaminophen; Cancer pain; Non malignant pain; Oxycodone; Oxymorphone

Indexed keywords

ACETAMINOPHEN PLUS OXYCODONE; ACETYLSALICYLIC ACID; AMIODARONE; ANALGESIC AGENT; CODEINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PLACEBO; QUINIDINE; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DIABETIC NEUROPATHY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; EUPHORIA; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; LIVER TOXICITY; LONG TERM CARE; LOW BACK PAIN; MIOSIS; NAUSEA; NONHUMAN; OSTEOARTHRITIS; PRURITUS; RESPIRATION DEPRESSION; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; TREATMENT INDICATION;

ANALGESICS, OPIOID; CHRONIC DISEASE; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; HUMANS; NEOPLASMS; OXYCODONE; PAIN;

EID: 33745292222     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Pöyhiã R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993;8:63-7.
2. Adams NJ, Plane MB, Fleming MF, Mundt MP, Saunders LA. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage 2001; 22:791-6.
3. Bolesta S, Haber SL. Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother 2002;36:331-3.
4. Gammaitoni AR, Galer BS, Lacouture P, Domingos J, Schlagheck T. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Medicine 2003;4:21-30.
5. Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 2003;1:84-92.
6. Rischitelli DG, Karbowicz SH. Safety and efficacy of controlled-release oxycodone: a systematic literature review. Pharmacotherapy 2002;22:898-904.
7. Leow KP, Wright AW, Cramond T, Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit 1993;15:440-7.
8. Pöyhiã R, Seppiala T. Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33:617-21.
9. Mandema JW, Kalko RF, Oshlak B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996;42:747-56.
10. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldnheim PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59:52-61.
11. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64:603-11.
12. Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18:271-9.
13. Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplanatation. J Clin Anesth 1996; 8:13-8.
14. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplanatation. Clin Pharmacol Ther 1997;61:655-61.
15. Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive doses of oxycodone and morphine produced marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 2000;84:421-8.
16. Benzinger DP, Miotto J, Grandy RP, Thomas GB, Swanthon RE, Fitzmartin RD. A pharmacokinetic / pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage 1997;13:75-82.
17. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47:639-46.
18. Pappagallo M, Heinberg LJ. Ethical issue in the management of chronic non-malignant pain. Semin Neurology 1997;17:203-11.
19. Bannwarth B. Risk-benefit assessment of opioids in chronic noncancer pain. Drug Safety 1999;21:283-96.
20. Roth SH. A new role for opioids in the treatment of arthritis. Drugs 2002;62:255-63.
21. Ackerman SJ, Moridn M, Reblando J, Xu X, Schein J, Vallow S, et al. Patient-reported utilization patterns of fentanyl transdermal system and CR oxycodone HCl among patient with chronic nonmalignant pain. J Manag Care Pharm 2003;9:223-31.
22. Jamison RN, Schein JR, Vallow S, Ascher S, Vorsanger GJ, Katz NP. Neuropsychological effects of long-term opioid use in chronic pain patients. J Pain Symptom Manage 2003;26:913-21.
23. Jamison RN, Raymond SA, Slawsby EA, Nedelijkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. Spine 1998;23:2591-600.
24. Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, et al. Efficacy and safety of CR versus IR oxycodone: randomized, double-blind evaluation in patients with cronic back pain. Clin J Pain 1999; 15:179-83.
25. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, et al. Treatment of osteoarthritis pain with CR oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol1999;26:862-9.
26. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-clock, controlled-release oxycodone therapy for ostheoafthritis-related pain. Arch Intern Med 2000;160:853-60.
27. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful dibetic neuropathy. Pain 2003;105:71-8.
28. Lipman AG. Treatment of chronic pain in osteoarthritis: do opioids have a clinical role? Curr Reumatology Rep 2001;3:513-9.
29. Hanks GV, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
30. Kaplan R, Parris WC, Citron ML, Zhuovsky D, Reder RF, Buckley BJ, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998;16:3230-7.
31. Parris WC, Johnson BW Jr, Croghan MK, Moore MR, Khojasteh A, Reder RF, et al. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 1998;16:205-11.
32. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled and immediate-release oxycodone in cancer patients. J Clin Pharmacol 2001;41:500-6.
33. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73:37-45.
34. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized, double-blind, crossover trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;16:3222-9.
35. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239-49.
36. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003;89:2027-30.
37. Heiskanen TE, Ruismaki PM, Seppala TA, Kalso EA. Morphine or oxycodone in cancer pain? Acta Oncol 2000; 39:941-7.
38. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79:1428-37.
39. Zhukovsky DS, Walsh D, Doona M. The relative potency between high dose oral oxycodone and intravenous morphine: a case illustration. J Pain Symptom Manage 1999;18:53-5.